Sano Genetics

Sano Genetics is a precision medicine software platform founded in 2017 by three Cambridge PhD students. The company aims to accelerate clinical trials by streamlining patient recruitment, genetic testing, and long-term engagement. Sano's mission is to enhance the accessibility of precision medicine by building a comprehensive source of genomic and biomedical data. The platform offers a 360° end-to-end solution that includes patient finding and recruitment, non-invasive genetic testing, electronic medical record retrieval, and customized patient engagement. Sano's innovative approach allows precision medicine teams to operate significantly faster and more cost-effectively. The company serves a diverse clientele, including pharmaceutical and biotech companies, academic researchers, and healthcare systems, and has expanded its reach to multiple regions, including the US, Canada, EU, UK, Australia, and New Zealand. Sano has successfully executed several impactful research initiatives, such as studies on Long COVID and ALS genetic testing. With a total funding of £11.8 million and a growing team of around 60 employees, Sano Genetics is recognized as a notable player in the field of precision medicine.